EUCTR2015-001072-22-FI进行中（未招募）不适用
Clinical and virological efficacy of pegylated interferon alpha in the treatment of rhinovirus infection in patients with primary hypogammaglobulinemia: randomized controlled trial - HypogammaInt1
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Adult patients (>18 years), primary hypogammaglobulinemia with regular immunoglobulin replacement therapy, rhinovirus positive from nasal swab, thrombocytes over 90 x10E9/L Neutrophiles > 1,5 x10E9/L and written informed consent.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 15
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 5
排除标准
- •Participation to another study, need for intensive care unit treatment, difficulties to understand national language, pregnancy and breastfeeding, any somatic, psychiatric or social disease or issue which in the opinion of the investigator makes participation in the trial not being in the best interest of the subject.
研究者
相似试验
尚未招募
不适用
Clinical trial of Iron supplement in anemic pregnant women.CTRI/2022/11/047376Generex Pharmassist Pvt. Ltd.
进行中（未招募）
不适用
Prospective study of patients treated with pegylated interferon-alpha 2b (PegIntron) for metastasizing ileal/coecal carcinoids - NAMetastasizing ileal/coecal carcinoids (WHO ICD-10 code: C17.9)EUCTR2006-002275-40-DKppsala University Hospital, Dept. of Medical Sciences90
进行中（未招募）
不适用
Prospective study of patients treated with pegylated interferon-alpha 2b (PegIntron) for metastasizing ileal/coecal carcinoids - NAMetastasizing ileal/coecal carcinoids (WHO ICD-10 code: C17.9)EUCTR2006-002275-40-SEppsala University Hospital, Dept. of Medical Sciences90
招募中
不适用
Investigation of clinical efficacy and safety of intramuscular administration of autologous total IgG therapy in patients with chronic urticariaDiseases of the skin and subcutaneous tissueKCT0006814Ajou University Hospital24
进行中（未招募）
1 期
Efficacy and safety of pegylated-proline-interferon alpha 2B (AOP2014) in maintaining deep molecular remissions in patients with chronic myeloid leukemia who discontinue ABL-kinase inhibitory therapy, with post-study follow-up.Chronic myeloid leukemiaMedDRA version: 21.0Level: LLTClassification code 10009016Term: Chronic myeloid leukemia in remissionSystem Organ Class: 100000004864EUCTR2016-001030-94-DEPhilipps University Marburg210